JAK-STAT signaling in hepatic fibrosis

Frontiers in Bioscience

Volumn 16, Issue 7, 2011, Pages 2794-2811

  Mair, Markus ^a   Blaas, Leander ^a   Österreicher, Christoph H ^b   Casanova, Emilio ^a   Eferl, Robert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cholestasis; Cirrhosis; Gp130; Growth hormone; IGF 1; IL 6; Liver fibrosis; STAT3; STAT5

Indexed keywords

JANUS KINASE; STAT PROTEIN;

ANIMAL; BIOLOGICAL MODEL; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER REGENERATION; LIVER TUMOR; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; JANUS KINASES; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER REGENERATION; MICE; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 79959549307     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3886     Document Type: Article

References (175)

1. M. Heron, D.L. Hoyert, S.L. Murphy, J. Xu, K.D. Kochanek and B. Tejada-Vera: Deaths: final data for 2006. Natl Vital Stat Rep 57, 1-134 (2009)
2. I.M. Bochkis, N.E. Rubins, P. White, E.E. Furth, J.R. Friedman and K.H. Kaestner: Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. Nat Med 14, 828-836 (2008)
3. J.A. Davila, R.O. Morgan, Y. Shaib, K.A. Mcglynn and H.B. El-Serag: Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127, 1372-1380 (2004) (Pubitemid 39457763)
4. H.B. El-Serag, J.A. Davila, N.J. Petersen and K.A. Mcglynn: The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139, 817-823 (2003)
5. G. Fattovich, T. Stroffolini, I. Zagni and F. Donato: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127, S35-50 (2004) (Pubitemid 39423368)
6. E.M. Brunt: Nonalcoholic steatohepatitis. Semin Liver Dis 24, 3-20 (2004) (Pubitemid 38496045)
7. P. Angulo: Nonalcoholic fatty liver disease. N Engl J Med 346, 1221-1231 (2002)
8. L. Benvegnu, M. Gios, S. Boccato and A. Alberti: Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53, 744-749 (2004) (Pubitemid 38561455)
9. G. Fattovich, M. Pantalena, I. Zagni, G. Realdi, S.W. Schalm and E. Christensen: Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 97, 2886-2895 (2002) (Pubitemid 35265444)
10. A. Sangiovanni, E. Del Ninno, P. Fasani, C. de Fazio, G. Ronchi, R. Romeo, A. Morabito, R. de Franchis and M. Colombo: Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126, 1005-1014 (2004) (Pubitemid 38451172)
11. H.B. El-Serag, M. Lau, K. Eschbach, J. Davila and J. Goodwin: Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med 167, 1983-1989 (2007) (Pubitemid 47606639)
12. H.E. Blum: Treatment of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 19, 129-145 (2005) (Pubitemid 40331502)
13. H.E. Blum: Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 11, 7391-7400 (2005) (Pubitemid 43126017)
14. R. Bataller and D.A. Brenner: Liver fibrosis. J Clin Invest 115, 209-218 (2005) (Pubitemid 40385459)
15. O.A. Gressner, M.S. Rizk, E. Kovalenko, R. Weiskirchen and A.M. Gressner: Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go? J Gastroenterol Hepatol 23, 1024-1035 (2008) (Pubitemid 352019381)
16. J.S. Duffield, S.J. Forbes, C.M. Constandinou, S. Clay, M. Partolina, S. Vuthoori, S. Wu, R. Lang and J.P. Iredale: Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115, 56-65 (2005) (Pubitemid 40385505)
17. S.L. Friedman: Hepatic fibrosis - overview. Toxicology 254, 120-129 (2008)
18. S.L. Friedman: Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655-1669 (2008) (Pubitemid 351615417)
19. S. Inokuchi, T. Aoyama, K. Miura, C.H. Osterreicher, Y. Kodama, K. Miyai, S. Akira, D.A. Brenner and E. Seki: Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci U S A 107, 844-849 (2010)
20. S. de Minicis, E. Seki, H. Uchinami, J. Kluwe, Y. Zhang, D.A. Brenner and R.F. Schwabe: Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 132, 1937-1946 (2007) (Pubitemid 46677935)
21. W.E. Naugler, T. Sakurai, S. Kim, S. Maeda, K. Kim, A.M. Elsharkawy and M. Karin: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121-124 (2007) (Pubitemid 47056470)
22. E. Seki, S. de Minicis, G.Y. Gwak, J. Kluwe, S. Inokuchi, C.A. Bursill, J.M. Llovet, D.A. Brenner and R.F. Schwabe: CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 119, 1858-1870 (2009)
23. F. Marra and C. Bertolani: Adipokines in liver diseases. Hepatology (2009)
24. S. de Minicis, E. Seki, C. Oesterreicher, B. Schnabl, R.F. Schwabe and D.A. Brenner: Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology 48, 2016-2026 (2008)
25. C. Weiler-Normann, J. Herkel and A.W. Lohse: Mouse models of liver fibrosis. Z Gastroenterol 45, 43-50 (2007) (Pubitemid 46202720)
26. D.E. Clouthier, S.A. Comerford and R.E. Hammer: Hepatic fibrosis, glomerulosclerosis, and a lipodystrophylike syndrome in PEPCK-TGF-beta1 transgenic mice. J Clin Invest 100, 2697-2713 (1997) (Pubitemid 28007537)
27. S. Kanzler, A.W. Lohse, A. Keil, J. Henninger, H.P. Dienes, P. Schirmacher, S. Rose-John, K.H. Zum Buschenfelde and M. Blessing: TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 276, G1059-1068 (1999) (Pubitemid 29214121)
28. N. Sanderson, V. Factor, P. Nagy, J. Kopp, P. Kondaiah, L. Wakefield, A.B. Roberts, M.B. Sporn and S.S. Thorgeirsson: Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A 92, 2572-2576 (1995)
29. E. Ueberham, R. Low, U. Ueberham, K. Schonig, H. Bujard and R. Gebhardt: Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology 37, 1067-1078 (2003) (Pubitemid 36538683)
30. P. Czochra, B. Klopcic, E. Meyer, J. Herkel, J.F. Garcia-Lazaro, F. Thieringer, P. Schirmacher, S. Biesterfeld, P.R. Galle, A.W. Lohse and S. Kanzler: Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 45, 419-428 (2006) (Pubitemid 44142114)
31. J.S. Campbell, S.D. Hughes, D.G. Gilbertson, T.E. Palmer, M.S. Holdren, A.C. Haran, M.M. Odell, R.L. Bauer, H.P. Ren, H.S. Haugen, M.M. Yeh and N. Fausto: Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A 102, 3389-3394 (2005) (Pubitemid 40328055)
32. H. Yoshiji, S. Kuriyama, Y. Miyamoto, U.P. Thorgeirsson, D.E. Gomez, M. Kawata, J. Yoshii, Y. Ikenaka, R. Noguchi, H. Tsujinoue, T. Nakatani, S.S. Thorgeirsson and H. Fukui: Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 32, 1248-1254 (2000)
33. P. Fickert, A. Fuchsbichler, M. Wagner, G. Zollner, A. Kaser, H. Tilg, R. Krause, F. Lammert, C. Langner, K. Zatloukal, H.U. Marschall, H. Denk and M. Trauner: Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127, 261-274 (2004) (Pubitemid 38962293)
34. T.H. Mauad, C.M. Van Nieuwkerk, K.P. Dingemans, J.J. Smit, A.H. Schinkel, R.G. Notenboom, M.A. Van Den Bergh Weerman, R.P. Verkruisen, A.K. Groen, R.P. Oude Elferink, M.A. Van Der Valk, P. Borst and G.J.A. Offerhaus: Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 145, 1237-1245 (1994)
35. Y. Popov, E. Patsenker, P. Fickert, M. Trauner and D. Schuppan: Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 43, 1045-1054 (2005) (Pubitemid 41627991)
36. E. Pikarsky, R.M. Porat, I. Stein, R. Abramovitch, S. Amit, S. Kasem, E. Gutkovich-Pyest, S. Urieli-Shoval, E. Galun and Y. Ben-Neriah: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461-466 (2004) (Pubitemid 39329586)
37. J.F. Bromberg: Activation of STAT proteins and growth control. Bioessays 23, 161-169 (2001) (Pubitemid 32116649)
38. T. Kisseleva, S. Bhattacharya, J. Braunstein and C.W. Schindler: Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285, 1-24 (2002) (Pubitemid 34246317)
39. T. Naka, M. Fujimoto and T. Kishimoto: Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. Trends Biochem Sci 24, 394-398 (1999) (Pubitemid 29450447)
40. D.F. Calvisi, S. Ladu, A. Gorden, M. Farina, E.A. Conner, J.S. Lee, V.M. Factor and S.S. Thorgeirsson: Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130, 1117-1128 (2006)
41. S. Desrivieres, C. Kunz, I. Barash, V. Vafaizadeh, C. Borghouts and B. Groner: The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition. J Mammary Gland Biol Neoplasia 11, 75-87 (2006) (Pubitemid 44309191)
42. D.R. Hodge, E.M. Hurt and W.L. Farrar: The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41, 2502-2512 (2005) (Pubitemid 41540626)
43. I. Najjar and R. Fagard: STAT1 and pathogens, not a friendly relationship. Biochimie 92, 425-444 (2010)
44. K. Schroder, P.J. Hertzog, T. Ravasi and D.A. Hume: Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75, 163-189 (2004) (Pubitemid 38174573)
45. T. Toyonaga, O. Hino, S. Sugai, S. Wakasugi, K. Abe, M. Shichiri and K. Yamamura: Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. Proc Natl Acad Sci U S A 91, 614-618 (1994) (Pubitemid 24041452)
46. F. Hong, B. Jaruga, W.H. Kim, S. Radaeva, O.N. El- Assal, Z. Tian, V.A. Nguyen and B. Gao: Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest 110, 1503-1513 (2002) (Pubitemid 35396921)
47. W.H. Kim, F. Hong, S. Radaeva, B. Jaruga, S. Fan and B. Gao: STAT1 plays an essential role in LPS/Dgalactosamine- induced liver apoptosis and injury. Am J Physiol Gastrointest Liver Physiol 285, G761-768 (2003) (Pubitemid 37151238)
48. B.D. Car, V.M. Eng, B. Schnyder, L. Ozmen, S. Huang, P. Gallay, D. Heumann, M. Aguet and B. Ryffel: Interferon gamma receptor deficient mice are resistant to endotoxic shock. J Exp Med 179, 1437-1444 (1994) (Pubitemid 24129561)
49. R. Sun and B. Gao: Negative regulation of liver regeneration by innate immunity (natural killer cells/interferon-gamma). Gastroenterology 127, 1525-1539 (2004) (Pubitemid 39457777)
50. R. Sun, O. Park, N. Horiguchi, S. Kulkarni, W.I. Jeong, H.Y. Sun, S. Radaeva and B. Gao: STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice. Hepatology 44, 955-966 (2006) (Pubitemid 46489560)
51. M.A. Meraz, J.M. White, K.C. Sheehan, E.A. Bach, S.J. Rodig, A.S. Dighe, D.H. Kaplan, J.K. Riley, A.C. Greenlund, D. Campbell, K. Carver-Moore, R.N. Dubois, R. Clark, M. Aguet and R.D. Schreiber: Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84, 431-442 (1996) (Pubitemid 26058568)
52. Z.Z. Zhu, J.Z. Di, W.Y. Gu, W.M. Cong, A. Gawron, Y. Wang, Q. Zheng, A.Z. Wang, G. Zhu, P. Zhang and L. Hou: Association of genetic polymorphisms in STAT1 gene with increased risk of hepatocellular carcinoma. Oncology 78, 382-388 (2010)
53. C. Park, S. Li, E. Cha and C. Schindler: Immune response in Stat2 knockout mice. Immunity 13, 795-804 (2000) (Pubitemid 32041802)
54. S. Radaeva, B. Jaruga, F. Hong, W.H. Kim, S. Fan, H. Cai, S. Strom, Y. Liu, O. El-Assal and B. Gao: Interferonalpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 122, 1020-1034 (2002) (Pubitemid 34267285)
55. H. Bender, M.Y. Wiesinger, C. Nordhoff, C. Schoenherr, C. Haan, S. Ludwig, R. Weiskirchen, N. Kato, P.C. Heinrich and S. Haan: Interleukin-27 displays interferon-gamma-like functions in human hepatoma cells and hepatocytes. Hepatology 50, 585-591 (2009)
56. A.M. Gamero, M.R. Young, R. Mentor-Marcel, G. Bobe, A.J. Scarzello, J. Wise and N.H. Colburn: STAT2 contributes to promotion of colorectal and skin carcinogenesis. Cancer Prev Res (Phila) 3, 495-504 (2010)
57. P.C. Heinrich, I. Behrmann, S. Haan, H.M. Hermanns, G. Muller-Newen and F. Schaper: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374, 1-20 (2003) (Pubitemid 37046923)
58. G. Ramadori and B. Christ: Cytokines and the hepatic acute-phase response. Semin Liver Dis 19, 141-155 (1999)
59. W. Northemann, M. Hattori, G. Baffet, T.A. Braciak, R.G. Fletcher, L.J. Abraham, J. Gauldie, M. Baumann and G.H. Fey: Production of interleukin 6 by hepatoma cells. Mol Biol Med 7, 273-285 (1990) (Pubitemid 20283939)
60. F. Hong, W.H. Kim, Z. Tian, B. Jaruga, E. Ishac, X. Shen and B. Gao: Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-x(L) proteins. Oncogene 21, 32-43 (2002) (Pubitemid 34076376)
61. C. Klein, T. Wustefeld, U. Assmus, T. Roskams, S. Rose-John, M. Muller, M.P. Manns, M. Ernst and C. Trautwein: The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest 115, 860-869 (2005) (Pubitemid 40489390)
62. Y. Masubuchi, M. Bourdi, T.P. Reilly, M.L. Graf, J.W. George and L.R. Pohl: Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem Biophys Res Commun 304, 207-212 (2003) (Pubitemid 36434217)
63. I.N. Hines, M. Kremer, F. Isayama, A.W. Perry, R.J. Milton, A.L. Black, C.L. Byrd and M.D. Wheeler: Impaired liver regeneration and increased oval cell numbers following T cell-mediated hepatitis. Hepatology 46, 229-241 (2007) (Pubitemid 47171940)
64. M. Mair, G. Zollner, D. Schneller, M. Musteanu, P. Fickert, J. Gumhold, C. Schuster, A. Fuchsbichler, M. Bilban, S. Tauber, H. Esterbauer, L. Kenner, V. Poli, L. Blaas, J.W. Kornfeld, E. Casanova, W. Mikulits, M. Trauner and R. Eferl: Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. Gastroenterology 138, 2499-2508 (2010)
65. T. Wuestefeld, C. Klein, K.L. Streetz, U. Betz, J. Lauber, J. Buer, M.P. Manns, W. Muller and C. Trautwein: Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration. J Bio Chem 278, 11281-11288 (2003) (Pubitemid 36792685)
66. A. Blindenbacher, X. Wang, I. Langer, R. Savino, L. Terracciano and M.H. Heim: Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology 38, 674-682 (2003) (Pubitemid 37052154)
67. H. Pan, F. Hong, S. Radaeva and B. Gao: Hydrodynamic gene delivery of interleukin-22 protects themouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol 1, 43-49 (2004)
68. S. Haga, K. Terui, H.Q. Zhang, S. Enosawa, W. Ogawa, H. Inoue, T. Okuyama, K. Takeda, S. Akira, T. Ogino, K. Irani and M. Ozaki: Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest 112, 989-998 (2003) (Pubitemid 38056314)
69. C.A. Camargo, Jr., J.F. Madden, W. Gao, R.S. Selvan and P.A. Clavien: Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 26, 1513-1520 (1997) (Pubitemid 27520017)
70. D.E. Cressman, L.E. Greenbaum, R.A. Deangelis, G. Ciliberto, E.E. Furth, V. Poli and R. Taub: Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274, 1379-1383 (1996) (Pubitemid 26391463)
71. T. Sakamoto, Z. Liu, N. Murase, T. Ezure, S. Yokomuro, V. Poli and A.J. Demetris: Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy. Hepatology 29, 403-411 (1999) (Pubitemid 29088443)
72. U. Dierssen, N. Beraza, H.H. Lutz, C. Liedtke, M. Ernst, H.E. Wasmuth and C. Trautwein: Molecular dissection of gp130-dependent pathways in hepatocytes during liver regeneration. J Biol Chem 283, 9886-9895 (2008)
73. W. Li, X. Liang, C. Kellendonk, V. Poli and R. Taub: STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem 277, 28411-28417 (2002) (Pubitemid 41079264)
74. Y. Nie, D.M. Erion, Z. Yuan, M. Dietrich, G.I. Shulman, T.L. Horvath and Q. Gao: STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol 11, 492-500 (2009)
75. H. Inoue, W. Ogawa, M. Ozaki, S. Haga, M. Matsumoto, K. Furukawa, N. Hashimoto, Y. Kido, T. Mori, H. Sakaue, K. Teshigawara, S. Jin, H. Iguchi, R. Hiramatsu, D. Leroith, K. Takeda, S. Akira and M. Kasuga: Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 10, 168-174 (2004) (Pubitemid 38524887)
76. S. Whittaker, R. Marais and A.X. Zhu: The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29, 4989-5005 (2010)
77. E.J. Park, J.H. Lee, G.Y. Yu, G. He, S.R. Ali, R.G. Holzer, C.H. Osterreicher, H. Takahashi and M. Karin: Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208 (2010)
78. S. Rebouissou, M. Amessou, G. Couchy, K. Poussin, S. Imbeaud, C. Pilati, T. Izard, C. Balabaud, P. Bioulac-Sage and J. Zucman-Rossi: Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457, 200-204 (2009)
79. W.E. Thierfelder, J.M. Van Deursen, K. Yamamoto, R.A. Tripp, S.R. Sarawar, R.T. Carson, M.Y. Sangster, D.A. Vignali, P.C. Doherty, G.C. Grosveld and J.N. Ihle: Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382, 171-174 (1996) (Pubitemid 26242884)
80. M.H. Kaplan, Y.L. Sun, T. Hoey and M.J. Grusby: Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382, 174-177 (1996) (Pubitemid 26242885)
81. S. Akira: Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 17, 138-146 (1999) (Pubitemid 29226664)
82. A. Kato, A. Graul-Layman, M.J. Edwards and A.B. Lentsch: Promotion of hepatic ischemia/reperfusion injury by IL-12 is independent of STAT4. Transplantation 73, 1142-1145 (2002) (Pubitemid 34415450)
83. Y. Cui, G. Riedlinger, K. Miyoshi, W. Tang, C. Li, C.X. Deng, G.W. Robinson and L. Hennighausen: Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol 24, 8037-8047 (2004) (Pubitemid 39167454)
84. Y. Cui, A. Hosui, R. Sun, K. Shen, O. Gavrilova, W. Chen, M.C. Cam, B. Gao, G.W. Robinson and L. Hennighausen: Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology 46, 504-513 (2007) (Pubitemid 47344786)
85. L. Hennighausen and G.W. Robinson: Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 22, 711-721 (2008) (Pubitemid 351439101)
86. C. Desbois-Mouthon, D. Wendum, A. Cadoret, C. Rey, P. Leneuve, A. Blaise, C. Housset, F. Tronche, Y. Le Bouc and M. Holzenberger: Hepatocyte proliferation during liver regeneration is impaired in mice with liver-specific IGF-1R knockout. FASEB J 20, 773-775 (2006) (Pubitemid 46671211)
87. P.A. Pennisi, J.J. Kopchick, S. Thorgeirsson, D. Leroith and S. Yakar: Role of growth hormone (GH) in liver regeneration. Endocrinology 145, 4748-4755 (2004) (Pubitemid 39281469)
88. D. Engblom, J.W. Kornfeld, L. Schwake, F. Tronche, A. Reimann, H. Beug, L. Hennighausen, R. Moriggl and G. Schutz: Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression. Genes Dev 21, 1157-1162 (2007) (Pubitemid 46789873)
89. G.B. Udy, R.P. Towers, R.G. Snell, R.J. Wilkins, S.H. Park, P.A. Ram, D.J. Waxman and H.W. Davey: Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A 94, 7239-7244 (1997) (Pubitemid 27345299)
90. X. Liu, G.W. Robinson, K.U. Wagner, L. Garrett, A. Wynshaw-Boris and L. Hennighausen: Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 11, 179-186. (1997) (Pubitemid 27081895)
91. T.K. Lee, K. Man, R.T. Poon, C.M. Lo, A.P. Yuen, I.O. Ng, K.T. Ng, W. Leonard and S.T. Fan: Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res 66, 9948-9956 (2006) (Pubitemid 44672047)
92. A. Hosui, A. Kimura, D. Yamaji, B.M. Zhu, R. Na and L. Hennighausen: Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-{beta} and STAT3 activation. J Exp Med 206, 819-831 (2009)
93. M.H. Kaplan, U. Schindler, S.T. Smiley and M.J. Grusby: Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4, 313-319 (1996) (Pubitemid 26132509)
94. K.M. Murphy and S.L. Reiner: The lineage decisions of helper T cells. Nat Rev Immunol 2, 933-944 (2002) (Pubitemid 37323214)
95. J. Iff, W. Wang, T. Sajic, N. Oudry, E. Gueneau, G. Hopfgartner, E. Varesio and I. Szanto: Differential proteomic analysis of STAT6 knockout mice reveals new regulatory function in liver lipid homeostasis. J Proteome Res 8, 4511-4524 (2009)
96. H. Yoshidome, A. Kato, M. Miyazaki, M.J. Edwards and A.B. Lentsch: IL-13 activates STAT6 and inhibits liver injury induced by ischemia/reperfusion. Am J Pathol 155, 1059-1064 (1999) (Pubitemid 29488913)
97. A. Kato, H. Yoshidome, M.J. Edwards and A.B. Lentsch: Reduced hepatic ischemia/reperfusion injury by IL-4: potential anti-inflammatory role of STAT6. Inflamm Res 49, 275-279 (2000) (Pubitemid 30451610)
98. A.B. Lentsch, A. Kato, B. Davis, W. Wang, C. Chao and M.J. Edwards: STAT4 and STAT6 regulate systemic inflammation and protect against lethal endotoxemia. J Clin Invest 108, 1475-1482 (2001) (Pubitemid 33091985)
99. B. Jaruga, F. Hong, R. Sun, S. Radaeva and B. Gao: Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes. J Immunol 171, 3233-3244 (2003) (Pubitemid 37093550)
100. B. Gao: Cytokines, STATs and liver disease. Cell Mol Immunol 2, 92-100 (2005)
101. P.J. Murray: The JAK-STAT signaling pathway: input and output integration. J Immunol 178, 2623-2629 (2007) (Pubitemid 46333135)
102. T. Ezure, T. Sakamoto, H. Tsuji, J.G. Lunz, 3rd, N. Murase, J.J. Fung and A.J. Demetris: The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol 156, 1627-1639 (2000) (Pubitemid 30646701)
103. W. Plum, D.F. Tschaharganeh, D.C. Kroy, E. Corsten, S. Erschfeld, U. Dierssen, H. Wasmuth, C. Trautwein and K.L. Streetz: Lack of glycoprotein 130/signal transducer and activator of transcription 3-mediated signaling in hepatocytes enhances chronic liver injury and fibrosis progression in a model of sclerosing cholangitis. Am J Pathol 176, 2236-2246
104. W. Plum, D.F. Tschaharganeh, D.C. Kroy, E. Corsten, S. Erschfeld, U. Dierssen, H. Wasmuth, C. Trautwein and K.L. Streetz: Lack of glycoprotein 130/signal transducer and activator of transcription 3-mediated signaling in hepatocytes enhances chronic liver injury and fibrosis progression in a model of sclerosing cholangitis. Am J Pathol 176, 2236-2246 (2010)
105. R. Taub: Hepatoprotection via the IL-6/Stat3 pathway. J Clin Invest 112, 978-980 (2003) (Pubitemid 38056310)
106. P. Dent, S.I. Han, C. Mitchell, E. Studer, A. Yacoub, J. Grandis, S. Grant, G.W. Krystal and P.B. Hylemon: Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. Biochem Pharmacol 70, 1685-1696 (2005) (Pubitemid 41540361)
107. L. Qiao, E. Studer, K. Leach, R. Mckinstry, S. Gupta, R. Decker, R. Kukreja, K. Valerie, P. Nagarkatti, W. El Deiry, J. Molkentin, R. Schmidt-Ullrich, P.B. Fisher, S. Grant, P.B. Hylemon and P. Dent: Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Mol Biol Cell 12, 2629-2645 (2001) (Pubitemid 33051930)
108. L. Qiao, A. Yacoub, E. Studer, S. Gupta, X.Y. Pei, S. Grant, P.B. Hylemon and P. Dent: Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology 35, 779-789 (2002) (Pubitemid 34258371)
109. Y.P. Rao, E.J. Studer, R.T. Stravitz, S. Gupta, L. Qiao, P. Dent and P.B. Hylemon: Activation of the Raf- 1/MEK/ERK cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes. Hepatology 35, 307-314 (2002) (Pubitemid 34106369)
110. C. Thomas, R. Pellicciari, M. Pruzanski, J. Auwerx and K. Schoonjans: Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7, 678-693 (2008)
111. A.J. Demetris, J.G. Lunz, 3rd, S. Specht and I. Nozaki: Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease. World J Gastroenterol 12, 3512-3522 (2006) (Pubitemid 43997028)
112. I. Nozaki, J.G. Lunz, 3rd, S. Specht, J.I. Park, A.S. Giraud, N. Murase and A.J. Demetris: Regulation and function of trefoil factor family 3 expression in the biliary tree. Am J Pathol 165, 1907-1920 (2004) (Pubitemid 39578370)
113. I. Nozaki, J.G. Lunz, 3rd, S. Specht, D.B. Stolz, K. Taguchi, V.M. Subbotin, N. Murase and A.J. Demetris: Small proline-rich proteins 2 are noncoordinately upregulated by IL-6/STAT3 signaling after bile duct ligation. Lab Invest 85, 109-123 (2005) (Pubitemid 40128045)
114. N.C. Tebbutt, A.S. Giraud, M. Inglese, B. Jenkins, P. Waring, F.J. Clay, S. Malki, B.M. Alderman, D. Grail, F. Hollande, J.K. Heath and M. Ernst: Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STATmediated trefoil gene activation in gp130 mutant mice. Nat Med 8, 1089-1097 (2002) (Pubitemid 35175963)
115. I.A. Leclercq, G.C. Farrell, R. Schriemer and G.R. Robertson: Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 37, 206-213 (2002) (Pubitemid 34833082)
116. F. Marra: Leptin and liver tissue repair: do rodent models provide the answers? J Hepatol 46, 12-18 (2007) (Pubitemid 44834430)
117. X. Ding, N.K. Saxena, S. Lin, A. Xu, S. Srinivasan and F.A. Anania: The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 166, 1655-1669 (2005) (Pubitemid 40734389)
118. N.K. Saxena, K. Ikeda, D.C. Rockey, S.L. Friedman and F.A. Anania: Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35, 762-771 (2002) (Pubitemid 34258369)
119. A.M. de Vos, M. Ultsch and A.A. Kossiakoff: Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306-312 (1992)
120. J. Woelfle, D.J. Chia and P. Rotwein: Mechanisms of growth hormone (GH) action. Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation. J Biol Chem 278, 51261-51266 (2003) (Pubitemid 38020363)
121. M.J. Waters, H.N. Hoang, D.P. Fairlie, R.A. Pelekanos and R.J. Brown: New insights into growth hormone action. J Mol Endocrinol 36, 1-7 (2006) (Pubitemid 43273660)
122. G.T. Ooi, K.R. Hurst, M.N. Poy, M.M. Rechler and Y.R. Boisclair: Binding of STAT5a and STAT5b to a single element resembling a gamma-interferon-activated sequence mediates the growth hormone induction of the mouse acid-labile subunit promoter in liver cells. Mol Endocrinol 12, 675-687 (1998) (Pubitemid 30659069)
123. M.G. Holloway, E.V. Laz and D.J. Waxman: Codependence of growth hormone-responsive, sexually dimorphic hepatic gene expression on signal transducer and activator of transcription 5b and hepatic nuclear factor 4alpha. Mol Endocrinol 20, 647-660 (2006) (Pubitemid 43291215)
124. X.Y. Shen, R.I. Holt, J.P. Miell, S. Justice, B. Portmann, M.C. Postel-Vinay and R.J. Ross: Cirrhotic liver expresses low levels of the full-length and truncated growth hormone receptors. J Clin Endocrinol Metab 83, 2532-2538 (1998) (Pubitemid 28503058)
125. A. Donaghy, R. Ross, A. Gimson, S.C. Hughes, J. Holly and R. Williams: Growth hormone, insulinlike growth factor-1, and insulinlike growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology 21, 680-688 (1995)
126. L. Caregaro, F. Alberino, P. Angeli and A. Gatta: Insulin-like growth factor 1 (IGF-1) in liver cirrhosis: a marker of hepatocellular dysfunction? J Hepatol 29, 342 (1998) (Pubitemid 28352823)
127. T.C. Chang, J.J. Lin, S.C. Yu and T.J. Chang: Absence of growth-hormone receptor in hepatocellular carcinoma and cirrhotic liver. Hepatology 11, 123-126 (1990)
128. N. Assy, Y. Pruzansky, D. Gaitini, Z. Shen Orr, Z. Hochberg and Y. Baruch: Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. J Hepatol 49, 34-42 (2008)
129. L.J. Murphy, K. Rajkumar and P. Molnar: Phenotypic manifestations of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 overexpression in transgenic mice. Prog Growth Factor Res 6, 425-432 (1995)
130. J.G. Scharf, F. Schmitz, J. Frystyk, C. Skjaerbaek, H. Moesus, W.F. Blum, G. Ramadori and H. Hartmann: Insulin-like growth factor-I serum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease. J Hepatol 25, 689-699 (1996) (Pubitemid 26373887)
131. J. Beattie, G.J. Allan, J.D. Lochrie and D.J. Flint: Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J 395, 1-19 (2006)
132. G.J. Allan, J. Beattie and D.J. Flint: Epithelial injury induces an innate repair mechanism linked to cellular senescence and fibrosis involving IGF-binding protein-5. J Endocrinol 199, 155-164 (2008)
133. I. Castilla-Cortazar, M. Garcia, B. Muguerza, J. Quiroga, R. Perez, S. Santidrian and J. Prieto: Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology 113, 1682-1691 (1997) (Pubitemid 27461257)
134. L. Sobrevals, C. Rodriguez, J.L. Romero-Trevejo, G. Gondi, I. Monreal, A. Paneda, N. Juanarena, S. Arcelus, N. Razquin, L. Guembe, G. Gonzalez- Aseguinolaza, J. Prieto and P. Fortes: Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology 51, 912-921 (2010)
135. N.Z. Canturk, Z. Canturk, M. Ozden, H. Dalcik, M. Yardimoglu and F. Tulubas: Protective effect of IGF-1 on experimental liver cirrhosis-induced common bile duct ligation. Hepatogastroenterology 50, 2061-2066 (2003) (Pubitemid 37467995)
136. C. Alexia, G. Fallot, M. Lasfer, G. Schweizer-Groyer and A. Groyer: An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 68, 1003-1015 (2004) (Pubitemid 39094263)
137. L. Blaas, J.W. Kornfeld, D. Schramek, M. Musteanu, G. Zollner, J. Gumhold, F. Van Zijl, D. Schneller, H. Esterbauer, G. Egger, M. Mair, L. Kenner, W. Mikulits, R. Eferl, R. Moriggl, J. Penninger, M. Trauner and E. Casanova: Disruption of the growth hormone-signal transducer and activator of transcription 5-insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology 51, 1319-1326 (2010)
138. S. Sanz, J.B. Pucilowska, S. Liu, C.M. Rodriguez- Ortigosa, P.K. Lund, D.A. Brenner, C.R. Fuller, J.G. Simmons, A. Pardo, M.L. Martinez-Chantar, J.A. Fagin and J. Prieto: Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury. Gut 54, 134-141 (2005) (Pubitemid 40007233)
139. A. Gentilini, D. Feliers, M. Pinzani, K. Woodruff and S. Abboud: Characterization and regulation of insulin-like growth factor binding proteins in human hepatic stellate cells. J Cell Physiol 174, 240-250 (1998) (Pubitemid 28112634)
140. A. Gentilini, F. Marra, P. Gentilini and M. Pinzani: Phosphatidylinositol-3 kinase and extracellular signalregulated kinase mediate the chemotactic and mitogenic effects of insulin-like growth factor-I in human hepatic stellate cells. J Hepatol 32, 227-234 (2000) (Pubitemid 30093901)
141. W.H. Kim, K. Matsumoto, K. Bessho and T. Nakamura: Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am J Pathol 166, 1017-1028 (2005) (Pubitemid 40524427)
142. A. Natarajan, B. Wagner and M. Sibilia: The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci U S A 104, 17081-17086 (2007) (Pubitemid 350210995)
143. I.M. Olazabal, J.A. Munoz, C. Rodriguez-Navas, L. Alvarez, E. Delgado-Baeza and J.P. Garcia-Ruiz: Prolactin's role in the early stages of liver regeneration in rats. J Cell Physiol 219, 626-633 (2009)
144. M. Wang, M. Chen, G. Zheng, B. Dillard, M. Tallarico, Z. Ortiz and A.X. Holterman: Transcriptional activation by growth hormone of HNF-6-regulated hepatic genes, a potential mechanism for improved liver repair during biliary injury in mice. Am J Physiol Gastrointest Liver Physiol 295, G357-366 (2008)
145. N. Omori, R.P. Evarts, M. Omori, Z. Hu, E.R. Marsden and S.S. Thorgeirsson: Expression of leukemia inhibitory factor and its receptor during liver regeneration in the adult rat. Lab Invest 75, 15-24 (1996) (Pubitemid 26250269)
146. O. Lahuna, M. Rastegar, D. Maiter, J.P. Thissen, F.P. Lemaigre and G.G. Rousseau: Involvement of STAT5 (signal transducer and activator of transcription 5) and HNF-4 (hepatocyte nuclear factor 4) in the transcriptional control of the hnf6 gene by growth hormone. Mol Endocrinol 14, 285-294 (2000) (Pubitemid 32295397)
147. M. Bertolotti, N. Carulli, D. Menozzi, F. Zironi, A. Digrisolo, A. Pinetti and M.G. Baldini: In vivo evaluation of cholesterol 7 alpha-hydroxylation in humans: effect of disease and drug treatment. J Lipid Res 27, 1278-1286 (1986) (Pubitemid 17009489)
148. J. Simon-Holtorf, H. Monig, H.J. Klomp, A. Reinecke-Luthge, U.R. Folsch and S. Kloehn: Expression and distribution of prolactin receptor in normal, fibrotic, and cirrhotic human liver. Exp Clin Endocrinol Diabetes 114, 584-589 (2006) (Pubitemid 46087265)
149. T. Hisaka, A. Desmouliere, J.L. Taupin, S. Daburon, V. Neaud, N. Senant, J.F. Blanc, J.F. Moreau and J. Rosenbaum: Expression of leukemia inhibitory factor (LIF) and its receptor gp190 in human liver and in cultured human liver myofibroblasts. Cloning of new isoforms of LIF mRNA. Comp Hepatol 3, 10 (2004)
150. M. Tomida, T. Heike and T. Yokota: Cytoplasmic domains of the leukemia inhibitory factor receptor required for STAT3 activation, differentiation, and growth arrest of myeloid leukemic cells. Blood 93, 1934-1941 (1999) (Pubitemid 29128495)
151. K.K. Kuropatwinski, C. de Imus, D. Gearing, H. Baumann and B. Mosley: Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6. J Biol Chem 272, 15135-15144 (1997) (Pubitemid 27255528)
152. E. Seki, Y. Kondo, Y. Iimuro, T. Naka, G. Son, T. Kishimoto, J. Fujimoto, H. Tsutsui and K. Nakanishi: Demonstration of cooperative contribution of MET- and EGFR-mediated STAT3 phosphorylation to liver regeneration by exogenous suppressor of cytokine signalings. J Hepatol 48, 237-245 (2008)
153. W.R. Swindell: Gene expression profiling of longlived dwarf mice: longevity-associated genes and relationships with diet, gender and aging. BMC Genomics 8, 353 (2007)
154. J.E. Rowland, A.M. Lichanska, L.M. Kerr, M. White, E.M. D'aniello, S.L. Maher, R. Brown, R.D. Teasdale, P.G. Noakes and M.J. Waters: In vivo analysis of growth hormone receptor signaling domains and their associated transcripts. Mol Cell Biol 25, 66-77 (2005) (Pubitemid 40039800)
155. W.I. Jeong, O. Park, S. Radaeva and B. Gao: STAT1 inhibits liver fibrosis in mice by inhibiting stellate cellproliferation and stimulating NK cell cytotoxicity. Hepatology 44, 1441-1451 (2006) (Pubitemid 44953650)
156. G.S. Baroni, L. D'ambrosio, P. Curto, A. Casini, R. Mancini, A.M. Jezequel and A. Benedetti: Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 23, 1189-1199 (1996) (Pubitemid 26137066)
157. Y. Inagaki, T. Nemoto, M. Kushida, Y. Sheng, K. Higashi, K. Ikeda, N. Kawada, F. Shirasaki, K. Takehara, K. Sugiyama, M. Fujii, H. Yamauchi, A. Nakao, B. de Crombrugghe, T. Watanabe and I. Okazaki: Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 38, 890-899 (2003) (Pubitemid 37221672)
158. D.C. Rockey and J.J. Chung: Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Investig Med 42, 660-670 (1994)
159. S. Radaeva, R. Sun, B. Jaruga, V.T. Nguyen, Z. Tian and B. Gao: Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing liganddependent manners. Gastroenterology 130, 435-452 (2006) (Pubitemid 43202042)
160. Z. Shi, A.E. Wakil and D.C. Rockey: Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A 94, 10663-10668 (1997) (Pubitemid 27430791)
161. N. Hiramatsu, N. Hayashi, A. Kasahara, H. Hagiwara, T. Takehara, Y. Haruna, M. Naito, H. Fusamoto and T. Kamada: Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 22, 135-142 (1995)
162. A.J. Muir, P.B. Sylvestre and D.C. Rockey: Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J Viral Hepat 13, 322-328 (2006)
163. S.E. Nicholson, D. de Souza, L.J. Fabri, J. Corbin, T.A. Willson, J.G. Zhang, A. Silva, M. Asimakis, A. Farley, A.D. Nash, D. Metcalf, D.J. Hilton, N.A. Nicola and M. Baca: Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci U S A 97, 6493-6498 (2000) (Pubitemid 30412741)
164. J. Schmitz, M. Weissenbach, S. Haan, P.C. Heinrich and F. Schaper: SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 275, 12848-12856 (2000) (Pubitemid 30241440)
165. H. Yasukawa, H. Misawa, H. Sakamoto, M. Masuhara, A. Sasaki, T. Wakioka, S. Ohtsuka, T. Imaizumi, T. Matsuda, J.N. Ihle and A. Yoshimura: The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. Embo J 18, 1309-1320 (1999) (Pubitemid 29110315)
166. T. Naka, H. Tsutsui, M. Fujimoto, Y. Kawazoe, H. Kohzaki, Y. Morita, R. Nakagawa, M. Narazaki, K. Adachi, T. Yoshimoto, K. Nakanishi and T. Kishimoto: SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFNgamma and IL-4 signaling in vivo. Immunity 14, 535-545 (2001) (Pubitemid 32520865)
167. T. Yoshida, H. Ogata, M. Kamio, A. Joo, H. Shiraishi, Y. Tokunaga, M. Sata, H. Nagai and A. Yoshimura: SOCS1 is a suppressor of liver fibrosis and hepatitisinduced carcinogenesis. J Exp Med 199, 1701-1707 (2004) (Pubitemid 38822003)
168. H. Ogata, T. Chinen, T. Yoshida, I. Kinjyo, G. Takaesu, H. Shiraishi, M. Iida, T. Kobayashi and A. Yoshimura: Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 25, 2520-2530 (2006)
169. A.W. Roberts, L. Robb, S. Rakar, L. Hartley, L. Cluse, N.A. Nicola, D. Metcalf, D.J. Hilton and W.S. Alexander: Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci U S A 98, 9324-9329 (2001) (Pubitemid 32743915)
170. X. Liu, P. Invernizzi, Y. Lu, R. Kosoy, Y. Lu, I. Bianchi, M. Podda, C. Xu, G. Xie, F. Macciardi, C. Selmi, S. Lupoli, R. Shigeta, M. Ransom, A. Lleo, A.T. Lee, A.L. Mason, R.P. Myers, K.M. Peltekian, C.N. Ghent, F. Bernuzzi, M. Zuin, F. Rosina, E. Borghesio, A. Floreani, R. Lazzari, G. Niro, A. Andriulli, L. Muratori, P. Muratori, P.L. Almasio, P. Andreone, M. Margotti, M. Brunetto, B. Coco, D. Alvaro, M.C. Bragazzi, F. Marra, A. Pisano, C. Rigamonti, M. Colombo, M. Marzioni, A. Benedetti, L. Fabris, M. Strazzabosco, P. Portincasa, V.O. Palmieri, C. Tiribelli, L. Croce, S. Bruno, S. Rossi, M. Vinci, C. Prisco, A. Mattalia, P. Toniutto, A. Picciotto, A. Galli, C. Ferrari, S. Colombo, G. Casella, L. Morini, N. Caporaso, A. Colli, G. Spinzi, R. Montanari, P.K. Gregersen, E.J. Heathcote, G.M. Hirschfield, K.A. Siminovitch, C.I. Amos, M.E. Gershwin and M.F. Seldin: Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 42, 658-660 (2010)
171. M.P. Gil, E. Bohn, A.K. O'guin, C.V. Ramana, B. Levine, G.R. Stark, H.W. Virgin and R.D. Schreiber: Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci U S A 98, 6680-6685 (2001) (Pubitemid 32538276)
172. C.V. Ramana, M.P. Gil, Y. Han, R.M. Ransohoff, R.D. Schreiber and G.R. Stark: Stat1-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci U S A 98, 6674-6679 (2001) (Pubitemid 32538275)
173. A.P. Costa-Pereira, S. Tininini, B. Strobl, T. Alonzi, J.F. Schlaak, H. Is'harc, I. Gesualdo, S.J. Newman, I.M. Kerr and V. Poli: Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc Natl Acad Sci U S A 99, 8043-8047. (2002) (Pubitemid 34651002)
174. K. Kovalovich, R.A. Deangelis, W. Li, E.E. Furth, G. Ciliberto and R. Taub: Increased toxin-induced liver injury and fibrosis in interleukin-6- deficient mice. Hepatology 31, 149-159 (2000) (Pubitemid 30033701)
175. D.C. Kroy, N. Beraza, D.F. Tschaharganeh, L.E. Sander, S. Erschfeld, A. Giebeler, C. Liedtke, H.E. Wasmuth, C. Trautwein and K.L. Streetz: Lack of interleukin-6/glycoprotein 130/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice. Hepatology 51, 463-473 (2010)